MYCOF News and Press, New Age Brands From 05/25/21

DENVER, May 25, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-so...

DENVER, May 19, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ...

Mydecine Innovations Group (MYCOF): Q1 GAAP EPS of -$0.03.Revenue of $16.01K vs. $4.58K a year agoAs of March 31, 2021, the Company had cash and cash equivalents of $11.3MPress Release For further details see: Mydecine Innovations Group reports Q1 results

DENVER, May 18, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA ) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternat...

DENVER, May 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative n...

This is Psychedellux – the leading recap of the week’s top news in the psychedelics industry. The Multidisciplinary Association of Psychedelic Studies ( MAPS ) released data from its Phase III trial with the FDA for the use of MDMA (ecst...

DENVER, May 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative n...

Mydecine Innovations Group Inc. (MYCOF) Q4 2020 Earnings Conference Call May 03, 2021 10:30 AM ET Company Participants Allison Soss - Investor Relations Josh Bartch - Co-founder, Chairman and CEO Dean Ditto - Chief Financial Officer Presentation Operator Greetings, and welcome to the Mydecine...

Mydecine Innovations Group (MYCOF): FY GAAP EPS of -$0.24.Cash and cash equivalents of of $2.2M.Press Release For further details see: Mydecine Innovations Group reports FY results

Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End Announced Appointm...